TriSalus Life Sciences, Inc. TLSIW

Annual Quarterly

Q2 FY2026 · ended Jun 30, 2026 · Revenue $11.41M, +1.7% YoY · Filed Aug 6, 2026

TriSalus Life Sciences, Inc. (TLSI) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $11.4 million and a net loss of $9.2 million. Free cash flow was -$10.2 million. As of Jun 30, 2026 it held $46.3 million in cash and investments and $33.1 million in total debt.

Revenue
$11.41M
+1.7% vs year-ago quarter
Net income
$-9.19M
-10.8% vs year-ago quarter
Operating cash flow
$-10.13M
-38.4% vs year-ago quarter
Free cash flow
$-10.21M
-37.7% vs year-ago quarter
EPS
$-0.16
+40.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
61.57M
+23.5% vs year-ago quarter
Net cash
$13.22M
Q2 FY2026
Operating margin
-67.7%
TTM

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
TLSI (Nasdaq), TLSIW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Westminster, CO
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1826667
Former names
MedTech Acquisition Corp (until Aug 10, 2023); MedTech Acquisition Corporation (until Oct 29, 2020)

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Revenue
$11.4M
$8.9M
$13.2M
$11.6M
$11.2M
Operating income
-$9.8M
-$8.4M
-$3.3M
-$9.0M
-$7.3M
Net income
-$9.2M
$1.5M
-$9.8M
-$10.8M
-$8.3M
Diluted EPS
-$0.16
$0.03
-$0.21
-$0.96
-$0.27
Operating cash flow
-$10.1M
-$6.5M
-$2.5M
-$3.7M
-$7.3M
Free cash flow
-$10.2M
-$6.6M
-$2.5M
-$3.9M
-$7.4M
Total assets
$62.4M
$71.0M
$35.3M
$36.5M
$41.3M
Total liabilities
$55.9M
$58.2M
$69.2M
$63.2M
$60.7M
Stockholders' equity
$6.5M
$12.8M
-$33.9M
-$26.7M
-$19.4M
Cash and investments
$46.3M
$56.6M
$20.4M
$22.7M
$26.5M
Total debt
$33.1M
$33.1M
$34.4M
$32.8M
$32.3M

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Sep 22, 2026 Sep 22, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 6, 2026 Aug 6, 2026
8-K Current report
Shareholder vote results
 May 14, 2026 May 14, 2026
10-Q Quarterly report May 12, 2026 Mar 31, 2026
8-K Current report
Results of operations
 May 12, 2026 May 12, 2026

All 493 TriSalus Life Sciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.